Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: results of an online tumor registry of clinical trials.

doi:10.1158/1078-0432.CCR-09-0888

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Back to search

Article

Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: results of an online tumor registry of clinical trials.

Clinical cancer research : an official journal of the American Association for Cancer Research - 15 Aug 2009

Jackman David M, Miller Vincent A, Cioffredi Leigh-Anne, Yeap Beow Y, Jänne Pasi A, Riely Gregory J, Ruiz Marielle Gallegos, Giaccone Giuseppe, Sequist Lecia V, Johnson Bruce E

Abstract excerpt

PURPOSE: The impact of epidermal growth factor receptor (EGFR) and KRAS genotypes on outcomes with erlotinib or gefitinib therapy continues to be debated. This study combines patient data from five trials in predominantly Western populations to assess the impact of EGFR and KRAS mutations on first-line therapy with an EGFR-tyrosine kinase inhibitor (TKI) and compare clinical versus molecular predictors of...

Topics

Adult
Aged
Aged, 80 and over
Antineoplastic Agents
Carcinoma, Non-Small-Cell Lung
Clinical Trials as Topic
Databases, Factual
ErbB Receptors
Erlotinib Hydrochloride

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Female

Gefitinib

Humans

Lung Neoplasms

Male

Middle Aged

Mutation

Online Systems

Prognosis

Source

Open in PubMed Open full text

Identifiers

PMID: 19671843
DOI: 10.1158/1078-0432.CCR-09-0888
PMCID: PMC3219530

Genes

EGFR
KRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 29 Aug 2026. Prepared record publication-19671843-2026-08-29.1. Manifest publication-graph-cohort-2026-08-29.1.

Source receipt: PubMed via Helena Literature Corpus, retrieved 29 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

discussions

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: results of an online tumor registry of clinical trials.PMID 19671843Read ↗

KRAS mutation as the biomarker of response to chemotherapy and EGFR-TKIs in patients with advanced non-small cell lung cancer: clues for its potential use in second-line therapy decision making.Semantic proximity Read ↗

Epidermal growth factor receptor (EGFR) mutations in a series of non-small-cell lung cancer (NSCLC) patients and response rate to EGFR-specific tyrosine kinase inhibitors (TKIs).Semantic proximity Read ↗

Optimization of patient selection for EGFR-TKIs in advanced non-small cell lung cancer by combined analysis of KRAS, PIK3CA, MET, and non-sensitizing EGFR mutations.Semantic proximity Read ↗

From clinical trials to clinical practice: predictors of response to erlotinib in advanced non-small cell lung cancer patients pretreated with chemotherapy.Semantic proximity Read ↗

Epidermal growth factor receptor mutations in non-small-cell lung cancer: implications for treatment and tumor biology.Semantic proximity Read ↗

EGFR Mutation Status and First-Line Treatment in Patients with Stage III/IV Non–Small Cell Lung Cancer in Germany: An Observational StudySemantic proximity Read ↗

Predictive and Prognostic Impact of Epidermal Growth Factor Receptor Mutation in Non–Small-Cell Lung Cancer Patients Treated With GefitinibSemantic proximity Read ↗

Epidermal growth factor receptor tyrosine kinase inhibitors as initial therapy for non-small cell lung cancer: focus on epidermal growth factor receptor mutation testing and mutation-positive patients.Semantic proximity Read ↗

Epidermal growth factor receptor mutations in non-small cell lung cancer: a basic science discovery with immediate clinical impact.Semantic proximity Read ↗

Outcome of advanced NSCLC patients harboring sensitizing EGFR mutations randomized to EGFR tyrosine kinase inhibitors or chemotherapy as first-line treatment: a meta-analysis.Semantic proximity Read ↗

KRAS mutations affect prognosis of non-small-cell lung cancer patients treated with first-line platinum containing chemotherapy.Semantic proximity Read ↗

Effectiveness of erlotinib treatment in advanced KRAS mutation-negative lung adenocarcinoma patients: Results of a multicenter observational cohort study (MOTIVATE).Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.